Inhibikase TherapeuticsIKT
Market Cap: $8.66M
About: Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Employees: 9
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
128% more capital invested
Capital invested by funds: $447K [Q1] → $1.02M (+$574K) [Q2]
8.24% more ownership
Funds ownership: 3.35% [Q1] → 11.59% (+8.24%) [Q2]
0% more funds holding
Funds holding: 12 [Q1] → 12 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Edward White 27% 1-year accuracy 33 / 122 met price target | 1,193%upside $15 | Buy Maintained | 16 Aug 2024 |